Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies - 2The most effective method to Pick the Best Material Organization: Insider Tips
- 3Lilly, Novo lock horns in India's obesity drug race
- 4Japan deploys the military to counter a surge in bear attacks
- 5Giude to Best Web based Learning Stage
- The Best Web-based Courses for Ability Advancement
- Benin coup thwarted by loyalist troops, president tells nation
- Terminal cancer diagnosis announced by JFK's granddaughter
- Instructions to Pick the Best Album Rates for Your Investment funds
- 2 ways you can conserve the water used to make your food
- Emergency services search for five people last seen in missing Jeep
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Ariana Grande and Jonathan Bailey will reunite for 'Sunday in the Park With George'
- 10 Delectable Specialty Mixed drinks
